68.20
price down icon1.37%   -0.95
after-market After Hours: 68.30 0.10 +0.15%
loading
Corcept Therapeutics Inc stock is traded at $68.20, with a volume of 853.03K. It is down -1.37% in the last 24 hours and down -6.86% over the past month. Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
See More
Previous Close:
$69.15
Open:
$69.15
24h Volume:
853.03K
Relative Volume:
0.65
Market Cap:
$7.23B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
54.13
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
-1.27%
1M Performance:
-6.86%
6M Performance:
+10.84%
1Y Performance:
+86.70%
1-Day Range:
Value
$67.75
$69.44
1-Week Range:
Value
$67.44
$70.44
52-Week Range:
Value
$32.33
$117.33

Corcept Therapeutics Inc Stock (CORT) Company Profile

Name
Name
Corcept Therapeutics Inc
Name
Phone
650.688.8803
Name
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Name
Employee
500
Name
Twitter
Name
Next Earnings Date
2025-02-17
Name
Latest SEC Filings
Name
CORT's Discussions on Twitter

Compare CORT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CORT
Corcept Therapeutics Inc
68.20 7.33B 628.56M 141.82M 142.60M 1.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.41 118.34B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.14 60.31B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
330.55 42.35B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.79 36.43B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
305.74 31.87B 3.81B -644.79M -669.77M -6.24

Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-06-23 Upgrade Truist Hold → Buy
Apr-11-23 Initiated SVB Securities Market Perform
Apr-04-23 Initiated Piper Sandler Overweight
Feb-15-23 Downgrade Jefferies Buy → Hold
Aug-01-22 Downgrade Truist Buy → Hold
Jul-27-22 Upgrade Jefferies Hold → Buy
Jun-27-22 Resumed Canaccord Genuity Buy
Feb-02-22 Initiated Canaccord Genuity Buy
Jan-28-22 Initiated Truist Buy
Aug-05-20 Downgrade Jefferies Buy → Hold
Sep-24-19 Initiated Jefferies Buy
Sep-06-19 Initiated H.C. Wainwright Buy
Feb-04-19 Downgrade B. Riley FBR Buy → Neutral
Aug-10-18 Reiterated Stifel Hold
May-31-18 Downgrade Stifel Buy → Hold
Mar-09-18 Initiated B. Riley FBR, Inc. Buy
Aug-31-17 Initiated Stifel Buy
Feb-02-17 Initiated Ladenburg Thalmann Buy
Apr-21-15 Initiated FBR Capital Outperform
Jan-13-14 Downgrade Stifel Buy → Hold
Aug-09-13 Downgrade Janney Buy → Neutral
Aug-09-13 Downgrade Ladenburg Thalmann Buy → Neutral
Feb-21-12 Reiterated JMP Securities Mkt Outperform
Jan-06-10 Upgrade Ladenburg Thalmann Neutral → Buy
Jul-17-08 Initiated Rodman & Renshaw Mkt Outperform
Jun-21-07 Upgrade Punk, Ziegel & Co Mkt Perform → Accumulate
View All

Corcept Therapeutics Inc Stock (CORT) Latest News

pulisher
Jul 29, 2025

Corcept Therapeutics' Q2 Earnings: A Critical Inflection Point for Growth and Innovation - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

What To Expect From Corcept’s (CORT) Q2 Earnings - FinancialContent

Jul 29, 2025
pulisher
Jul 29, 2025

Technical Charts Suggest Momentum Shift in Corcept Therapeutics IncorporatedSmart Allocation Stock Pick Insights Gaining Interest - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

Published on: 2025-07-28 23:53:14 - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

When is Corcept Therapeutics Incorporated stock expected to show significant growthCapitalize on momentum-driven investment opportunities - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Why Corcept Therapeutics Incorporated stock attracts strong analyst attention Daily Equity Signal Strength Summary Report - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

What are the technical indicators suggesting about Corcept Therapeutics IncorporatedAchieve rapid capital gains with smart investing - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT) - Yahoo Finance

Jul 28, 2025
pulisher
Jul 27, 2025

Why is Corcept Therapeutics Incorporated stock attracting strong analyst attentionFree Investment Community - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk - Yahoo Finance

Jul 27, 2025
pulisher
Jul 25, 2025

10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey

Jul 25, 2025
pulisher
Jul 25, 2025

Corcept Therapeutics’ ALS Study: A Potential Game-Changer? - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Should I buy Corcept Therapeutics Incorporated stock before earningsHigh-octane financial growth - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Is Corcept Therapeutics Incorporated a good long term investmentConsistent high-performance stocks - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Corcept Therapeutics Incorporated stock priceUnbelievable profit margins - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Corcept Therapeutics Incorporated stockExceptional financial outcomes - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

Is Corcept Therapeutics Incorporated stock overhyped or has real potentialFree Market Dynamics Reports - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant - Yahoo.co

Jul 24, 2025
pulisher
Jul 24, 2025

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call - Business Wire

Jul 24, 2025
pulisher
Jul 23, 2025

Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects - Yahoo Finance

Jul 23, 2025
pulisher
Jul 21, 2025

Corcept Therapeutics Incorporated Stock Analysis and ForecastConsistently outstanding ROI - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Corcept Therapeutics (NASDAQ:CORT): A High-Conviction Buy in the Biopharma Sector Amid EPS Growth and Strategic Momentum - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Is Well Worth Watching - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - Benzinga

Jul 21, 2025
pulisher
Jul 20, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) is largely controlled by institutional shareholders who own 70% of the company - simplywall.st

Jul 20, 2025
pulisher
Jul 18, 2025

agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know - Yahoo Finance

Jul 18, 2025
pulisher
Jul 17, 2025

FDA approval sought of relacorilant for platinum-resistant ovarian cancer - Rare Cancer News

Jul 17, 2025
pulisher
Jul 16, 2025

M&T Bank Corp Sells 3,530 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares of Stock - Defense World

Jul 15, 2025
pulisher
Jul 15, 2025

Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Why Corcept Therapeutics Incorporated stock attracts strong analyst attentionShort Term Profit Focus - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How rare disease-focused Corcept Therapeutics expanded into cancerSan Francisco Business Times - The Business Journals

Jul 15, 2025
pulisher
Jul 14, 2025

Corcept seeks FDA approval for ovarian cancer treatment (CORT) - Seeking Alpha

Jul 14, 2025
pulisher
Jul 14, 2025

Corcept Therapeutics' Relacorilant NDA Submission: A Breakthrough in Ovarian Cancer and a Strategic Pivot to Oncology - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Corcept Therapeutics Submits New Drug Application to FDA - TipRanks

Jul 14, 2025
pulisher
Jul 14, 2025

Corcept Therapeutics Files New Drug Application for Treatment of Platinum-Resistant Ovarian Cancer - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire

Jul 14, 2025

Corcept Therapeutics Inc Stock (CORT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.38
price up icon 10.28%
$37.27
price up icon 0.57%
$105.00
price up icon 3.19%
$26.74
price down icon 2.59%
$111.48
price down icon 1.16%
biotechnology ONC
$305.74
price up icon 3.81%
Cap:     |  Volume (24h):